Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Comparing and sequencing T-DM1 and T-DXd in HER2+ breast cancer

Jean-Yves Pierga • 16 May 2024
ESMO Breast 2024
Breast Cancer Antibodies Pertuzumab Trastuzumab deruxtecan Trastuzumab emtansine
DESTINY-Breast06

Jean-Yves Pierga, MD, PhD, Institut Curie, Paris, France, examines the role of trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) for patients with HER2+ breast cancer. Results from the DESTINY-Breast06 trial (NCT04784715) compared the two antibody-drug conjugates, with T-DXd being superior. However, additional research is being conducted to further elucidate the role of T-DM1 in the metastatic setting. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jean-Yves Pierga

Optimal sequencing of trastuzumab deruxtecan in HER2+ breast cancer
0:46
Optimal sequencing of trastuzumab deruxtecan in HER2+ breast cancer
Jean-Yves Pierga • 18 Oct 2025
Incidence and management of T-DXd-induced ILD in breast cancer
0:46
Incidence and management of T-DXd-induced ILD in breast cancer
Jean-Yves Pierga • 18 Oct 2025
REALITY-01: final results of real-world T-DXd in HER2+ metastatic breast cancer
1:56
REALITY-01: final results of real-world T-DXd in HER2+ metastatic breast cancer
Jean-Yves Pierga • 18 Oct 2025
Assessing the real-world side effects of T-DXd in HER2+ breast cancer
0:58
Assessing the real-world side effects of T-DXd in HER2+ breast cancer
Jean-Yves Pierga • 18 Oct 2025

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals